retatrutide eli lilly press release 2024 2025 Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Retatrutide Isn't the Endgame. Brenipatide

Individual factors such as baseline gut sensitivity, concurrent medications (especially metformin, which can independently cause diarrhea), and pre-existing conditions like irritable bowel syndrome significantly influence whether diarrhea develops and its severity

Antioxidant Protection As weve established, glutathione is a potent antioxidant

#FoodSafety #FMCG #RegulatoryCompliance #CleanLabel #CPGIndustry #StateRegulation #Reformulation To view or add a comment, sign in CPG analysts are reading the GLP-1 story too uniformly

doi: 10.1111/dom.12639 84 ManigaultKRThurstonMM

Advances in formulation, such as mucoadhesive systems, have helped prolong drug contact, optimize concentration gradients, and improve bioavailability